clinical trial

Do Physicians and Researchers Profit and Trade Stock on Privileged Information

by

An interesting article titled “Do Physicians/Researchers Trade Stock Based on Privileged Information?” written by Elie Donath and Mark J. Eisenberg appears in the Summer 2012 issue of The Journal of Law, Medicine & Ethics (vol. 40, issue 2, pages 391-393). Speculation is made that “…physicians/researchers are inappropriately profiting (by buying or selling stock) from information derived from advance copies of high-impact clinical trial data distributed by medical conferences or journals.” A case study is made looking at the American Society of Clinical Oncology. Up until 2008 ASCO selectively and discreetly distributed abstracts from all forthcoming presentations at the ASCO Conference to ASCO members 2 weeks prior to them becoming publicly accessible at the conference. The authors used multiple linear regression to look at the percentage change in stock price on the first trading day following the release of these abstracts. A … Read more

The Right to Health and Information

by

An interesting article is written by Trudo Lemmens and Candice Telfer titled “Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency,” which appeared in the 2011 issue of the American Journal of Law and Medicine (vol. 38, pages 63-112). In the article the authors argue that information about clinical trials should be recognized as a fundamental component of the right to health. The authors make a mention of two controversies in recent years. The first is of GlaxoSmithKline and its use of the antidepressant Paxil for treatment of depression in the pediatric population. In 2004, the Attorney General of New York prosecuted GSK for allegedly hiding negative data, selective publishing of positive data, and use of skewed publications to promote off-label prescriptions. The second case is the mention of Vioxx in which the … Read more